EGFR and colorectal carcinoma: Nonetheless and most remarkably, KRAS mutant CRC cells, which correspond to the subset of patients who are currently excluded from EGFR targeted therapies, were sensitive to PI3K p110α inhibition regardless of the additional alterations.